CordenPharma Becomes Supplier Partner of the PSCI (Pharmaceutical Supply Chain Initiative)

27 March 2025 -- Basel, Switzerland -- We are excited to announce that as of March 2025, after successfully fulfilling the requirements for supplier partnership, CordenPharma have been selected to become a Supplier Partner in the second cohort of the PSCI (Pharmaceutical Supply Chain Initiative).

PSCI is a non-profit association that brings together partners in the pharmaceutical and healthcare industry who share a common vision of ensuring acceptable working conditions, safe processes and facilities, economic development, and environmental sustainability in local communities.
The PSCI’s approach is grounded in five key responsible business practices and supply chain management standards:

• Ethics
• Labor
• Health & Safety
• Environment
• Management Systems

The PSCI audit program of our manufacturing sites assesses our performance against these five responsible business practices and supply chain management standards.
During the preparation phase for this partnership, CordenPharma excelled in several key areas, including the handling of high-potency compounds, behavior-based safety (BBS) programs, and risk management practices.

This partnership not only addresses audit requirements from our customers but also supports the continued implementation of CordenPharma’s sustainable procurement program.

William Cashin, Chief Quality & Compliance Officer at CordenPharma comments, “I am proud of the hard work across our global teams on sustainability. Our employees are delighted to achieve supplier partnership status and to demonstrate our commitment to the PSCI Principles. We look forward to sharing future audit results and Maturity Models with transparency and collaborating with customer PSCI members towards our common goal.”

About CordenPharma
CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization. With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency). The CordenPharma Group is comprised of 11 facilities across Europe and North America. In the 2024 financial year, the organization generated sales of €854 million and had over 3,000 employees. In 2022, CordenPharma was acquired by Astorg – a leading Pan-European private equity firm with deep expertise in the healthcare sector – to accelerate its development and further strengthen its leadership in the CDMO peptide space. Please visit cordenpharma.com.